Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2024 · 10-Q
Revenue$924.94K$924.94K−15.8% vs Q2 2023 Net Income-$1.44M-$1.44MN/M vs Q2 2023 EPS Diluted-$0.89-$0.89N/M vs Q2 2023 Gross Profit-$1,015,386N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$72,726N/M Margins · derivedGross margin-109.8%−96.4 pt vs Q2 2023
Operating margin-150.4%−108.9 pt vs Q2 2023
Net margin-155.5%−101.5 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end